摘要
目的分析总结极重度COPD稳定期联合应用福莫特罗粉／布地奈德及噻托溴铵治疗的临床价值。方法将100例COPD患者随机分为A、B、C3组，A组34例，给予福莫特罗粉／布地奈德治疗；B组33例，给予噻托溴铵治疗；C组34例，给予联合福莫特罗粉／布地奈德及噻托溴铵治疗。对比3组临床治疗效果。结果3组接受治疗前FEV1、FEV1／FVC、FEV1％pred及圣乔治呼吸问卷（SGRQ）评分比较差异无统计学意义（P〉0．05），但经治疗3个月后，3组FEV1、FEV1／FVC、FEV1%pred及SGRQ比较差异有统计学意义（P〈0．05），C组明显优于A组及B组（P〈0．05），而A组与B组比较，差异无统计学意义（P〉0．05）；同时3组药物不良反应发生率比较，差异无统计学意义（P〉0．05）。结论COPD稳定期患者联合应用福莫特罗粉／布地奈德及噻托溴铵治疗可在不增加药物不良反应的同时显著提高治疗效果。
Objective Analysis summary very severe chronic obstructive pulmonary disease （COPD） plateau joint application f ROM mott powder/budesonide and consult the clinical value of bromide treatment. Methods One hundred COPD patients were randomly divided into A, B, C three groups,A group of 34 cases, giving Mr Mott powder/budesonide treatment, B group of 33 cases, give thiamethoxam bromide treatment,C group of 34 cases,gives the joint f ROM mott powder/budesonide and thiamethoxam bromide treatment. Compared three groups of clinical therapeutic effect. Results Three groups of treatment before the first second forced expiratory volume （FEV1）, FEV1/FVC and forced vital capacity ratio,FEV1 percentage of predicted value （FEV1 %pred） and st Georgers respiratory questionnaire score （SGRQ） is no statistical significance （ P 〉0.05）, but after 3 months treatment, the three groups of FEV1 , FEV1/FVC1 FEV1 % pred and SGRQ comparing statistical differences （ P 〈0.05）, group C is superior to group A and group B （ P 〈0.05）, and group A and group B was no statistical difference （ P 〉0.05）. And three groups of drug side effects incidence is no statistical difference （ P 〉0.05）. Conclusions Patients with COPD stabilization combined use of f ROM mott powder/budesonide and thiamethoxam bromide treatment can without any increase in adverse drug reactions and improve therapeutic effect.
出处
《国际呼吸杂志》
2015年第9期667-669,共3页
International Journal of Respiration
关键词
慢性阻塞性肺疾病
稳定期
福莫特罗粉/布地奈德
噻托溴铵
Chronic obstructive pulmonary disease
Stability
F ROM mott powder/hudesonide
Thiamethoxam Joe bromide
